Cargando…

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer

The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.(1) Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siddiqui, Bilal A., Subudhi, Sumit K., Sharma, Padmanee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Spotlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044095/ https://www.ncbi.nlm.nih.gov/pubmed/35492243 http://dx.doi.org/10.1016/j.xcrm.2022.100613

Ejemplares similares

The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma
por: van Laarhoven, Hanneke W.M., et al.
Publicado: (2023)

An unexpected role for PD-L1 in front–rear polarization and directional migration
por: Sánchez-Álvarez, Miguel, et al.
Publicado: (2022)

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle
por: Bakhoum, Samuel F., et al.
Publicado: (2021)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

What does time mean in development?
por: Ebisuya, Miki, et al.
Publicado: (2018)

What sugar does to your pores
por: Kohler, Jennifer J.
Publicado: (2021)

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
por: Graff, Julie N., et al.
Publicado: (2016)

How to survive a pandemic
por: Burki, Talha
Publicado: (2022)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

ARF3 weights the balance for prostate cancer metastasis
por: Caswell, Patrick T.
Publicado: (2023)

Mammalian fertilization: Does sperm IZUMO1 mediate fusion as well as adhesion?
por: Bianchi, Enrica, et al.
Publicado: (2023)

Making safe sense of an anti-sense!
por: Gill, Upkar S., et al.
Publicado: (2022)

Cholinergic anti-inflammatory pathway and COVID-19
por: Mehranfard, Danial, et al.
Publicado: (2022)

Advances in co-opting anti-depressant drugs in glioma therapy
por: Pant, Ayush, et al.
Publicado: (2022)

New insights into IRE1α activation and function in anti-tumor immunity
por: Logue, Susan E., et al.
Publicado: (2022)

Decrypting the potency of anti-cancer therapeutics by using mass spectrometry to quantify post-translational modifications
por: Herbst, Sophie A., et al.
Publicado: (2023)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2022)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
por: Bilen, Mehmet Asim, et al.
Publicado: (2016)

Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer
por: Bishop, Jennifer, et al.
Publicado: (2014)

S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
por: Wagner, Nikolaus B, et al.
Publicado: (2018)

Enzalutamide Prior to Radium-223 Is Associated with Better Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Compared to Abiraterone—A Retrospective Study
por: Chen, Hao Xiang, et al.
Publicado: (2023)

A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus
por: Oxford, J S, et al.
Publicado: (2003)

New migraine prophylaxis compounds from serendipity: gambling or wisdom?
Publicado: (2004)

Heightening the awareness of headache disorders
Publicado: (2004)

Academic specialist education in headache medicine. Next move for the headache community
por: Martelletti, Paolo
Publicado: (2005)

The road ahead for chronic headache patients
por: Martelletti, P.
Publicado: (2006)

Patent foramen ovale and migraine: no reason to intervene
por: Diener, Hans-Christoph
Publicado: (2007)

Advances in epigenome-wide association studies for common diseases
por: Paul, Dirk S., et al.
Publicado: (2014)

Localised ABA signalling mediates root growth plasticity
por: Ding, Zhaojun, et al.
Publicado: (2013)

Distorting the metric fabric of the cognitive map
por: Jeffery, Kate J.
Publicado: (2015)

Shooting through time: new insights from transcriptomic data
por: Harrison, C. Jill
Publicado: (2015)

Decoding Rich Spatial Information with High Temporal Resolution
por: Stokes, Mark G., et al.
Publicado: (2015)

CTLA-4 and Autoimmunity: New Twists in the Tale
por: Walker, Lucy S.K.
Publicado: (2015)

Sensing the enemy within: how macrophages detect intracellular Gram-negative bacteria
por: Demon, Dieter, et al.
Publicado: (2014)

Imaging latent tuberculosis infection with radiolabeled nitroimidazoles
por: Ankrah, Alfred O., et al.
Publicado: (2016)

Health status after detoxification in medication overuse headache
por: Martelletti, Paolo
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_3l1gvj87hvsk7uvgc25f6basvs